

DPP9 deficiency: an Inflammasomopathy

which can be rescued by lowering NLRP1/IL-1 signaling

Cassandra R. HARAPAS^{1,2,\$}, Kim S. ROBINSON^{3,\$}, Kenneth LAY^{4,\$}, Jasmine WONG⁴, Annick RAAS-ROTHSCHILD⁵, Bertrand BOISSON^{6,7,8}, Scott B. DRUTMAN⁶, Pawat LAOHAMONTHONKUL^{1,2}, Devon BONNER⁹, Mark GORRELL¹⁰, Sophia DAVIDSON^{1,2}, Chien-Hsiung YU^{1,2}, Hulya KAYSERILI¹¹, Nevin HATIPOGLU¹², Jean-Laurent CASANOVA^{6,7,8,13,14}, Jonathan A. BERNSTEIN¹⁵, Franklin L. ZHONG^{3,*}, Seth L. MASTERS^{1,2,*}, Bruno REVERSADE^{4,10,16*}

Affiliations:

1. Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
2. Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia
3. SRIS, A*STAR, Singapore
4. Genome Institute of Singapore (GIS), A*STAR, Singapore
5. The Institute for Rare Diseases, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
6. St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA
7. Paris University, Imagine Institute, Paris, France
8. Laboratory of Human Genetics of Infectious Disease, Necker Branch, INSERM U1163, Paris, France
9. Center for Undiagnosed Diseases, Stanford University School of Medicine, Stanford, CA, USA.
10. Centenary Institute, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.
11. Medical Genetics Department, Koç University School of Medicine (KUSOM), Istanbul, Turkey.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

12. Department of Pediatric Infection, Health Science University, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
13. Pediatric Immunology-Hematology Unit, Assistance Publique-Hôpitaux de Paris, Necker Hospital for Sick Children, Paris, France
14. Howard Hughes Medical Institute, New York, USA
15. Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
16. Institute of Molecular and Cellular Biology (IMCB), A*STAR, Singapore

§ These authors contributed equally to this work

* Joint senior authors to whom correspondence should be addressed:

Franklin Zhong (franklin.zhong@ntu.edu.sg)

Seth Masters (masters@wehi.edu.au)

Bruno Reversade (bruno@reversade.com)

Abstract:

Dipeptidyl peptidase 9 (DPP9) is a direct inhibitor of NLRP1, but how it impacts inflammasome regulation in vivo is not yet established. Here, we report two families with immune-associated defects, skin pigmentation abnormalities and neurological deficits that segregate with biallelic *DPP9* rare variants. Using patient-derived primary cells and biochemical assays, these variants are shown to behave as hypomorphic or loss-of-function alleles that fail to repress NLRP1. Remarkably, the removal in mice, of a single copy of either *Nlrp1a/b/c*, *Asc*, *Gsdmd*, *Il-1r*, but not *Il-18*, was sufficient to rescue the lethality of *Dpp9* mutant neonates. These experiments suggest that the deleterious consequences of DPP9 loss are mainly driven by the aberrant activation of the canonical NLRP1 inflammasome and IL-1 β signaling. Collectively, our results delineate a Mendelian disorder of DPP9 deficiency driven by increased NLRP1 activity as demonstrated in patient cells and in a mouse model of the disease.

One Sentence Summary:

Loss of DPP9 activity in humans and mice results in pathogenic NLRP1 overactivation.

The human NLRP1 inflammasome is a multi-protein complex that is triggered by viral infections(1, 2) or danger-associated signals(3), resulting in the release of proinflammatory cytokines, including IL-1 family members, IL-1 β and IL-18(4). Dysregulation of the human NLRP1 inflammasome is associated with a range of inflammatory Mendelian diseases such as Multiple Self-healing Palmoplantar Carcinoma (MSPC, MIM615225)(5), Juvenile Recurrent Respiratory Papillomatosis (JRRP, 618803MIM)(6), and Autoinflammation with Arthritis and Dyskeratosis (AIADK, MIM617388)(7). In the absence of any cognate triggers, inflammasome sensors in the family of Nod-like receptors (NLRs) are maintained in an inactive state by a number of regulatory proteins. For example, NLRP1 is bound to, and repressed by, the enzymatic activity and scaffolding function of dipeptidyl peptidase 9 (DPP9) and DPP8(7, 8). The role of DPP9 as a negative regulator of human or mouse NLRP1 has been established through pharmacological inhibition of DPP9 and inactivation of DPP9 in cell lines in vitro, but its function has not been documented in vivo.

As part of a cohort of patients with inborn errors of immunity, we studied a child (F2: II.3) with signs of susceptibility to infections consisting of recurrent facial HSV lesions and airway inflammation, including chronic intermittent asthma and primary pulmonary tuberculosis. Exome sequencing disclosed a germline homozygous stop-gained mutation (c.2551C>T; p.Q851*) in *DPP9* ([MIM608258](#)) (Fig. 1, A, B and E) which was heterozygous in the parents. A second child (F1: II.1) was identified with help of the GeneMatcher(9) database and carried compound heterozygous *DPP9* variants with a paternal missense mutation (c.449G>A, p.G167S) and a maternal early truncating mutation (c.641C>G; p.S214*) (Fig. 1, A to C). Both children shared a triad of symptoms summarized in Table 1 which partially overlapped with NLRP1 gain-of-function mutations causing AIADK(7). This consisted of a general failure to thrive, skin manifestations and blood anomalies, which in the case of F1: II.1 required hematopoietic stem cell transplant. The stop-gain mutations found in the two probands are expected to completely abolish the enzymatic activity of DPP9, as its catalytic domain is situated at the C-terminus. The missense mutation p.(G167S) found in proband F1: II.1 affects a residue in a flexible loop that is located at the periphery of the DPP9 substrate binding site (Fig. 1D). Thus, the DPP9^{G167S} mutation is predicted to diminish the substrate binding and/or catalytic efficiency. To date, no homozygous damaging variants have been reported for *DPP9* which according to genomAD is significantly averse to loss-of-function mutations(10).

To investigate the impact of the *DPP9* variants on mRNA expression and enzymatic function, primary skin cells were isolated from affected patients of both families (Fig. 2A). When compared with control primary fibroblasts, and those derived from the heterozygous parents of family 2 (F2: I.3 and I.4), a significant decrease in DPP9 protein was found in the proband's (F1: II.1) fibroblasts. This was consistent with one allele not encoding the full-length protein due to an early stop mutation p.S214* (Fig. 2A, lanes 1 and 2). Notably, we could not observe any endogenous DPP9 protein in the proband of family 2 (F2: II.3), indicating that the stop-gain mutant (p.Q851*) was degraded via the nonsense-mediated decay pathway (Fig. 2A, lanes 1 and 5). Thus, the p.Q851* *DPP9* variant probably yields a loss-of-expression, resulting in a protein-null allele. We next sought to assess the enzymatic activity of the DPP9^{G167S} variant towards a model substrate Gly-Pro-AMC (Fig. 2B and fig. S1A). The p.G167S mutation was found to reduce the enzymatic activity to ~15% of that of wild-type DPP9.

Given that DPP9 has been identified as a specific interacting partner and inhibitor of human and mouse NLRP1(7, 8), we measured the ability of DPP9^{WT}, catalytically-dead DPP9^{S759A} or the patient DPP9^{G167S} mutant to repress NLRP1 when re-expressed in DPP8/DPP9 double KO 293T-ASC-GFP reporter cells (Fig. 2C and fig. S1, B and C). Exogenous DPP9^{WT} repressed NLRP1-dependent ASC-GFP speck formation. In contrast, both DPP9^{S759A} and DPP9^{G167S} were less effective in inhibiting ASC speck formation. Taken together, these experiments suggest that these DPP9 patient variants are less able to maintain NLRP1 in the inactive state.

We and others have demonstrated that NLRP1 is the most prominent inflammasome sensor in human keratinocytes and that these cells readily undergo pyroptotic cell death in response to NLRP1 activation(5, 11). Using primary keratinocytes isolated from family 2 and the Luminex platform, we found that the cytokine and chemokine profile of the proband differed from those of his heterozygous parents (fig. S1D). We demonstrated that the proband keratinocytes, as do keratinocytes from patients with gain-of-function NLRP1 mutations(5), spontaneously secreted active IL-1 β and IL-18 into the media without any exogenous stimulus. Despite measurable IL-1 release visualised by ELISA and western blot (Fig. 2, D and E respectively), the patient's keratinocytes were viable in culture and could be serially cultured (fig. S1E) for at least 4 passages. This cytokine release was also accompanied by

ASC oligomerization, as demonstrated using a DSS crosslinking assay, and GSDMD cleavage (Fig. 2E). These data are consistent with a small fraction of the cells undergoing spontaneous inflammasome activation, without overt pyroptosis. A similar phenomenon has been documented in murine macrophages(12).

To dissect the pathogenicity of the loss of DPP9 in vivo, we took advantage of the DPP9 mutant mouse line which carries the catalytic-dead DPP9 p.S729A mutation. Homozygous *Dpp9*^{S729A/S729A} knock-in mice die within 24 hours of birth(13, 14). Based on our results obtained in patient-derived primary cells, we examined whether this lethality might be associated with overactivation of the NLRP1 inflammasome. Indeed, homozygous loss of all *Nlrp1* alleles (*Nlrp1a/b/c*, herein referred to as *Nlrp1*) protect *Dpp9*^{S729A/S729A} mice from neonatal lethality. Furthermore, deletion of even a single *Nlrp1* allele was also sufficient to generate viable animals (Fig. 3A and fig. S2, A and B). *Dpp9*^{S729A/S729A}*Nlrp1*^{-/-} mice were healthy and proved to be fertile, although runted compared to *Dpp9*^{S729A/+}*Nlrp1*^{-/-} siblings (Fig. 3, A and B). Short stature of *Dpp9*^{S729A/S729A}*Nlrp1*^{-/-} was associated with decreased hip width but relatively conserved limb width (Fig. 3, C and D).

At birth (day 0), *Dpp9*^{S729A/S729A} mice appeared normal and were suckling, as evidenced by a milk spot (Fig. 3E). We used flow cytometry to characterise immune cell populations in the blood of *Dpp9*^{S729A/S729A} mutant mice sufficient, heterozygous or deficient for NLRP1, along with relevant controls. Numbers of monocytes, dendritic cells, T cells, B cells, NK cells and neutrophils in the bone marrow were comparable between all genotypes assessed (Fig. 3F and fig. S2D). This is consistent with viable fetal liver chimeras that have previously been generated from this line(15, 16). In contrast, we observed a dramatic and specific monocytopenia affecting Ly6C^{med} and dendritic cells in the blood (Fig. 3G and fig. S2, C and D). This corresponds with cell types that have the highest expression levels of *Nlrp1a* and *Nlrp1b*(17) (fig. S2E) and indeed, monocytopenia is rescued by the heterozygous or homozygous loss of *Nlrp1* (Fig 3G). Thus, the haematopoietic abnormality and lethality caused by germline loss of DPP9 activity in mice is largely driven by overactive NLRP1 signaling.

In order to determine NLRP1-independent effects of DPP9 loss of function we further interrogated the *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} line. Aside from being runted, *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} mice had a slight decrease in life expectancy (Fig. 3H) compared to control lines. *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} mice also displayed immune infiltrate in the lungs which contained

foamy macrophages (F4/80+), B cells (B220+) and T cells (CD3+) post 6 months of age (Fig. 3I and fig. S3, A and B). While histological analysis of other organs and automated blood cell analysis showed no overt differences between genotypes (fig. S3, C to F). Overall, these results suggest inflammasome-independent roles of DPP9 relating to stature and lung inflammation, which is consistent with the broad range of processes regulated by DPP9. Decreased stature and lung inflammation were also recorded in DPP9-deficient patients (Table 1). Notably, two GWAS studies have implicated germline DPP9 variants in the development of pulmonary fibrosis(18, 19) and severe COVID19 pathology(20).

To further dissect the contribution of downstream components of the NLRP1 signalling axis, we next crossed *Dpp9*^{S729A/S729A} mice with strains deficient for effectors of the NLRP1 inflammasome. Both heterozygous and homozygous loss of *Asc*, *Gsdmd* and *Il-1r* rescued *Dpp9*^{S729A/S729A} neonatal lethality to a similar extent as *Nlrp1* deficiency (Fig. 3J). Interestingly, the biallelic loss of *Il-18* did not rescue DPP9 loss of function (Fig. 3J) suggesting that *Il-1* may be the main driver of the disease. Rescued mice exhibited a similar phenotype to *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} mice, appearing healthy yet runted. For example, *Dpp9*^{S729A/S729A} *Gsdmd*^{-/-} mice did not gain weight at the same rate as controls, and developed the same immune cell infiltrate in their lungs as *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} mice at 6 months of age, despite normal blood cell counts (fig. S4). The number of rescued *Dpp9*^{S729A/S729A} mice that survived to weaning age fell significantly below Mendelian ratios (Fig. 3J). However, these numbers might be confounded by potential cannibalisation of the runted pups. Overall it is clear that the deletion of a single allele of either *Asc*, *Gsdmd* or *Il-1r* is sufficient to protect *Dpp9*^{S729A/S729A} mice. These results raise the possibility that even partial inhibition of the NLRP1-inflammasome pathway, with anti-IL-1 β antibodies for example, would provide some therapeutic benefit for DPP9 deficient patients. In further support of this, anti-IL-1 β therapy was partially successful in a patient harbouring a germline NLRP1 p.P1214R mutation which abrogated binding and therefore inhibition by DPP9(21).

In summary, we have identified two unrelated families with autosomal recessive DPP9 deficiency, which is characterised by immune-associated defects, dermatological anomalies and neurological deficits. This Mendelian disease bears some degree of resemblance with auto-immune disorders caused by NLRP1 activating mutations. In particular the AIADK-causing NLRP1 p.P1214R mutation which entirely abrogates DPP9 binding and inhibition of NLRP1, is expected to yield comparable phenotypes(7). Both diseases appear to

manifest with recurrent episodes of fevers, auto-immune anemia and a general failure to thrive (Table 1). The milder skin manifestations seen in DPP9 patients may be explained by the presence of active DPP8 which we have shown can compensate for DPP9 deficiency in human cells(7).

Using biochemical and cellular assays, we demonstrated that all patient-derived *DPP9* alleles had reduced catalytic activity and were defective in suppressing the NLRP1 inflammasome in vitro. These results suggest that the patients' symptoms are at least in part due to the aberrant activation of the NLRP1 inflammasome. This notion was validated by in vivo experiments: the neonatal lethality of *Dpp9* mutant mice was rescued by the deletion of *Nlrp1* and downstream inflammasome signaling components *Asc*, *Gsdmd* and *Il-r1*. Thus IL-1 β inhibition might be a viable therapeutic strategy for these patients. Recent studies have shown that human DPP9 has many cellular substrates and also represses an orthologous inflammasome sensor, CARD8, which is absent in rodents(22–25). These findings could account for the broad spectrum of symptoms in patients with DPP9 mutations, some of which might not be modelled in mice. Overall, our results delineate a new human Mendelian disease of germline DPP9 deficiency, whose pathogenesis is largely driven by the aberrant activation of the NLRP1 inflammasome.

References and Notes:

1. K. S. Robinson, D. E. T. Teo, K. S. Tan, G. A. Toh, H. H. Ong, C. K. Lim, K. Lay, B. V. Au, T. S. Lew, J. J. H. Chu, V. T. K. Chow, D. Y. Wang, F. L. Zhong, B. Reversade, Enteroviral 3C protease activates the human NLRP1 inflammasome in airway epithelia. *Science*. **370** (2020), doi:10.1126/science.aay2002.
2. S. Bauernfried, M. J. Scherr, A. Pichlmair, K. E. Duderstadt, V. Hornung, Human NLRP1 is a sensor for double-stranded RNA. *Science* (2020), doi:10.1126/science.abd0811.
3. G. Fenini, S. Grossi, E. Contassot, T. Biedermann, E. Reichmann, L. E. French, H.-D. Beer, Genome Editing of Human Primary Keratinocytes by CRISPR/Cas9 Reveals an Essential Role of the NLRP1 Inflammasome in UVB Sensing. *J. Invest. Dermatol.* **138**, 2644–2652 (2018).
4. P. Broz, V. M. Dixit, Inflammasomes: mechanism of assembly, regulation and signalling. *Nat. Rev. Immunol.* **16**, 407–420 (2016).
5. F. L. Zhong, O. Mamaï, L. Sborgi, L. Boussofara, R. Hopkins, K. Robinson, I. Szeverényi, T. Takeichi, R. Balaji, A. Lau, H. Tye, K. Roy, C. Bonnard, P. J. Ahl, L. A. Jones, P. J. Baker, L. Lacina, A. Otsuka, P. R. Fournie, F. Malecaze, E. B. Lane, M. Akiyama, K. Kabashima, J. E. Connolly, S. L. Masters, V. J. Soler, S. S. Omar, J. A. McGrath, R. Nedelcu, M. Gribaa, M. Denguezli, A. Saad, S. Hiller, B. Reversade, Germline NLRP1 Mutations Cause Skin Inflammatory and Cancer Susceptibility Syndromes via Inflammasome Activation. *Cell*. **167**, 187–202.e17 (2016).

6. S. B. Drutman, F. Haerynck, F. L. Zhong, D. Hum, N. J. Hernandez, S. Belkaya, F. Rapaport, S. J. de Jong, D. Creytens, S. J. Tavernier, K. Bonte, S. De Schepper, J. van der Werff Ten Bosch, L. Lorenzo-Diaz, A. Wullaert, X. Bossuyt, G. Orth, V. R. Bonagura, V. Béziat, L. Abel, E. Jouanguy, B. Reversade, J.-L. Casanova, Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 19055–19063 (2019).
7. F. L. Zhong, K. Robinson, D. E. T. Teo, K.-Y. Tan, C. Lim, C. R. Harapas, C.-H. Yu, W. H. Xie, R. M. Sobota, V. B. Au, R. Hopkins, A. D’Oswaldo, J. C. Reed, J. E. Connolly, S. L. Masters, B. Reversade, Human DPP9 represses NLRP1 inflammasome and protects against autoinflammatory diseases via both peptidase activity and FIIND domain binding. *J. Biol. Chem.* **293**, 18864–18878 (2018).
8. M. C. Okondo, D. C. Johnson, R. Sridharan, E. B. Go, A. J. Chui, M. S. Wang, S. E. Poplawski, W. Wu, Y. Liu, J. H. Lai, D. G. Sanford, M. O. Arciprete, T. R. Golub, W. W. Bachovchin, D. A. Bachovchin, DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. *Nat. Chem. Biol.* **13**, 46–53 (2017).
9. N. Sobreira, F. Schiettecatte, D. Valle, A. Hamosh, GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum. Mutat.* **36**, 928–930 (2015).
10. K. J. Karczewski, L. C. Francioli, G. Tiao, B. B. Cummings, J. Alföldi, Q. Wang, R. L. Collins, K. M. Laricchia, A. Ganna, D. P. Birnbaum, L. D. Gauthier, H. Brand, M. Solomonson, N. A. Watts, D. Rhodes, M. Singer-Berk, E. M. England, E. G. Seaby, J. A. Kosmicki, R. K. Walters, K. Tashman, Y. Farjoun, E. Banks, T. Poterba, A. Wang, C. Seed, N. Whiffin, J. X. Chong, K. E. Samocha, E. Pierce-Hoffman, Z. Zappala, A. H. O’Donnell-Luria, E. V. Minikel, B. Weisburd, M. Lek, J. S. Ware, C. Vittal, I. M. Armean, L. Bergelson, K. Cibulskis, K. M. Connolly, M. Covarrubias, S. Donnelly, S. Ferriera, S. Gabriel, J. Gentry, N. Gupta, T. Jeandet, D. Kaplan, C. Llanwarne, R. Munshi, S. Novod, N. Petrillo, D. Roazen, V. Ruano-Rubio, A. Saltzman, M. Schleicher, J. Soto, K. Tibbetts, C. Tolonen, G. Wade, M. E. Talkowski, Genome Aggregation Database Consortium, B. M. Neale, M. J. Daly, D. G. MacArthur, The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature.* **581**, 434–443 (2020).
11. J. Sand, E. Haertel, T. Biedermann, E. Contassot, E. Reichmann, L. E. French, S. Werner, H.-D. Beer, Expression of inflammasome proteins and inflammasome activation occurs in human, but not in murine keratinocytes. *Cell Death Dis.* **9**, 24 (2018).
12. C. L. Evavold, J. Ruan, Y. Tan, S. Xia, H. Wu, J. C. Kagan, The Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages. *Immunity.* **48**, 35–44.e6 (2018).
13. M. G. Gall, Y. Chen, A. J. Vieira de Ribeiro, H. Zhang, C. G. Bailey, D. S. Spielman, D. M. T. Yu, M. D. Gorrell, Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality. *PLoS One.* **8**, e78378 (2013).
14. M. Kim, M. Minoux, A. Piaia, B. Kueng, B. Gapp, D. Weber, C. Haller, S. Barbieri, K. Namoto, T. Lorenz, J. Wirsching, F. Bassilana, W. Dietrich, F. M. Rijli, I. Ksiazek, DPP9 enzyme activity controls survival of mouse migratory tongue muscle progenitors and its absence leads to neonatal lethality due to suckling defect. *Dev. Biol.* **431**, 297–308 (2017).
15. M. Kim, L. von Muenchow, T. Le Meur, B. Kueng, B. Gapp, D. Weber, W. Dietrich, J. Kovarik, A. G. Rolink, I. Ksiazek, DPP9 enzymatic activity in hematopoietic cells is dispensable for mouse hematopoiesis. *Immunol. Lett.* **198**, 60–65 (2018).
16. M. G. Gall, H. E. Zhang, Q. Lee, C. J. Jolly, G. W. McCaughan, A. Cook, B. Roediger, M. D. Gorrell, Immune regeneration in irradiated mice is not impaired by the absence of DPP9

- enzymatic activity. *Sci. Rep.* **9**, 7292 (2019).
17. J. Choi, T. M. Baldwin, M. Wong, J. E. Bolden, K. A. Fairfax, E. C. Lucas, R. Cole, C. Biben, C. Morgan, K. A. Ramsay, A. P. Ng, M. Kauppi, L. M. Corcoran, W. Shi, N. Wilson, M. J. Wilson, W. S. Alexander, D. J. Hilton, C. A. de Graaf, Haemopedia RNA-seq: a database of gene expression during haematopoiesis in mice and humans. *Nucleic Acids Res.* **47**, D780–D785 (2019).
 18. T. E. Fingerlin, E. Murphy, W. Zhang, A. L. Peljto, K. K. Brown, M. P. Steele, J. E. Loyd, G. P. Cosgrove, D. Lynch, S. Groshong, H. R. Collard, P. J. Wolters, W. Z. Bradford, K. Kossen, S. D. Seiwert, R. M. du Bois, C. K. Garcia, M. S. Devine, G. Gudmundsson, H. J. Isaksson, N. Kaminski, Y. Zhang, K. F. Gibson, L. H. Lancaster, J. D. Cogan, W. R. Mason, T. M. Maher, P. L. Molyneaux, A. U. Wells, M. F. Moffatt, M. Selman, A. Pardo, D. S. Kim, J. D. Crapo, B. J. Make, E. A. Regan, D. S. Walek, J. J. Daniel, Y. Kamatani, D. Zelenika, K. Smith, D. McKean, B. S. Pedersen, J. Talbert, R. N. Kidd, C. R. Markin, K. B. Beckman, M. Lathrop, M. I. Schwarz, D. A. Schwartz, Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. *Nat. Genet.* **45**, 613–620 (2013).
 19. R. J. Allen, B. Guillen-Guio, J. M. Oldham, S.-F. Ma, A. Dressen, M. L. Paynton, L. M. Kraven, M. 'en Obeidat, X. Li, M. Ng, R. Braybrooke, M. Molina-Molina, B. D. Hobbs, R. K. Putman, P. Sakornsakolpat, H. L. Booth, W. A. Fahy, S. P. Hart, M. R. Hill, N. Hirani, R. B. Hubbard, R. J. McAnulty, A. B. Millar, V. Navaratnam, E. Oballa, H. Parfrey, G. Saini, M. K. B. Whyte, Y. Zhang, N. Kaminski, A. Adegunsoye, M. E. Streck, M. Neighbors, X. R. Sheng, G. Gudmundsson, V. Gudnason, H. Hatabu, D. J. Lederer, A. Manichaikul, J. D. Newell Jr, G. T. O'Connor, V. E. Ortega, H. Xu, T. E. Fingerlin, Y. Bossé, K. Hao, P. Joubert, D. C. Nickle, D. D. Sin, W. Timens, D. Furniss, A. P. Morris, K. T. Zondervan, I. P. Hall, I. Sayers, M. D. Tobin, T. M. Maher, M. H. Cho, G. M. Hunninghake, D. A. Schwartz, B. L. Yaspan, P. L. Molyneaux, C. Flores, I. Noth, R. G. Jenkins, L. V. Wain, Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med.* **201**, 564–574 (2020).
 20. E. Pairo-Castineira, S. Clohisey, L. Klaric, A. D. Bretherick, K. Rawlik, D. Pasko, S. Walker, N. Parkinson, M. H. Fourman, C. D. Russell, J. Furniss, A. Richmond, E. Gountouna, N. Wrobel, D. Harrison, B. Wang, Y. Wu, A. Meynert, F. Griffiths, W. Oosthuyzen, A. Kousathanas, L. Moutsianas, Z. Yang, R. Zhai, C. Zheng, G. Grimes, R. Beale, J. Millar, B. Shih, S. Keating, M. Zechner, C. Haley, D. J. Porteous, C. Hayward, J. Yang, J. Knight, C. Summers, M. Shankar-Hari, P. Klenerman, L. Turtle, A. Ho, S. C. Moore, C. Hinds, P. Horby, A. Nichol, D. Maslove, L. Ling, D. McAuley, H. Montgomery, T. Walsh, A. Pereira, A. Renieri, GenOMICC Investigators, ISARICC Investigators, COVID-19 Human Genetics Initiative, 23andMe Investigators, BRACOVIC Investigators, Gen-COVID Investigators, X. Shen, C. P. Ponting, A. Fawkes, A. Tenesa, M. Caulfield, R. Scott, K. Rowan, L. Murphy, P. J. M. Openshaw, M. G. Semple, A. Law, V. Vitart, J. F. Wilson, J. K. Baillie, Genetic mechanisms of critical illness in Covid-19. *Nature* (2020), doi:10.1038/s41586-020-03065-y.
 21. S. Grandemange, E. Sanchez, P. Louis-Plence, F. Tran Mau-Them, D. Bessis, C. Coubes, E. Frouin, M. Seyger, M. Girard, J. Puechberty, V. Costes, M. Rodière, A. Carbasse, E. Jeziorski, P. Portales, G. Sarrabay, M. Mondain, C. Jorgensen, F. Apparailly, E. Hoppenreijns, I. Touitou, D. Geneviève, A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis). *Ann. Rheum. Dis.* **76**, 1191–1198 (2017).
 22. D. Justa-Schuch, M. Silva-Garcia, E. Pilla, M. Engelke, M. Kilisch, C. Lenz, U. Möller, F. Nakamura, H. Urlaub, R. Geiss-Friedlander, DPP9 is a novel component of the N-end rule pathway targeting the tyrosine kinase Syk. *Elife.* **5** (2016), doi:10.7554/eLife.16370.
 23. A. R. Griswold, D. P. Ball, A. Bhattacharjee, A. J. Chui, S. D. Rao, C. Y. Taabazuing, D. A. Bachovchin, DPP9's Enzymatic Activity and Not Its Binding to CARD8 Inhibits Inflammasome

- Activation. *ACS Chemical Biology*. **14** (2019), pp. 2424–2429.
24. A. R. Griswold, P. Cifani, S. D. Rao, A. J. Axelrod, M. M. Miele, R. C. Hendrickson, A. Kentsis, D. A. Bachovchin, A Chemical Strategy for Protease Substrate Profiling. *Cell Chem Biol*. **26**, 901–907.e6 (2019).
 25. D. C. Johnson, M. C. Okondo, E. L. Orth, S. D. Rao, H.-C. Huang, D. P. Ball, D. A. Bachovchin, DPP8/9 inhibitors activate the CARD8 inflammasome in resting lymphocytes. *Cell Death Dis*. **11**, 628 (2020).
 26. Y. Yang, D. M. Muzny, F. Xia, Z. Niu, R. Person, Y. Ding, P. Ward, A. Braxton, M. Wang, C. Buhay, N. Veeraraghavan, A. Hawes, T. Chiang, M. Leduc, J. Beuten, J. Zhang, W. He, J. Scull, A. Willis, M. Landsverk, W. J. Craigen, M. R. Bekheirnia, A. Stray-Pedersen, P. Liu, S. Wen, W. Alcaraz, H. Cui, M. Walkiewicz, J. Reid, M. Bainbridge, A. Patel, E. Boerwinkle, A. L. Beaudet, J. R. Lupski, S. E. Plon, R. A. Gibbs, C. M. Eng, Molecular findings among patients referred for clinical whole-exome sequencing. *JAMA*. **312**, 1870–1879 (2014).
 27. Y. Yang, D. M. Muzny, J. G. Reid, M. N. Bainbridge, A. Willis, P. A. Ward, A. Braxton, J. Beuten, F. Xia, Z. Niu, M. Hardison, R. Person, M. R. Bekheirnia, M. S. Leduc, A. Kirby, P. Pham, J. Scull, M. Wang, Y. Ding, S. E. Plon, J. R. Lupski, A. L. Beaudet, R. A. Gibbs, C. M. Eng, Clinical whole-exome sequencing for the diagnosis of mendelian disorders. *N. Engl. J. Med*. **369**, 1502–1511 (2013).
 28. H. Li, R. Durbin, Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics*. **26**, 589–595 (2010).
 29. A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K. Garimella, D. Altshuler, S. Gabriel, M. Daly, M. A. DePristo, The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res*. **20**, 1297–1303 (2010).
 30. H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis, R. Durbin, 1000 Genome Project Data Processing Subgroup, The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. **25**, 2078–2079 (2009).
 31. I. A. Adzhubei, S. Schmidt, L. Peshkin, V. E. Ramensky, A. Gerasimova, P. Bork, A. S. Kondrashov, S. R. Sunyaev, A method and server for predicting damaging missense mutations. *Nat. Methods*. **7**, 248–249 (2010).
 32. M. Kircher, D. M. Witten, P. Jain, B. J. O’Roak, G. M. Cooper, J. Shendure, A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet*. **46**, 310–315 (2014).
 33. P. C. Ng, S. Henikoff, Predicting deleterious amino acid substitutions. *Genome Res*. **11**, 863–874 (2001).
 34. P. Maffucci, B. Bigio, F. Rapaport, A. Cobat, A. Borghesi, M. Lopez, E. Patin, A. Bolze, L. Shang, M. Bendavid, E. M. Scott, P. D. Stenson, C. Cunningham-Rundles, D. N. Cooper, J. G. Gleeson, J. Fellay, L. Quintana-Murci, J.-L. Casanova, L. Abel, B. Boisson, Y. Itan, Blacklisting variants common in private cohorts but not in public databases optimizes human exome analysis. *Proc. Natl. Acad. Sci. U. S. A*. **116**, 950–959 (2019).
 35. Y. Itan, L. Shang, B. Boisson, M. J. Ciancanelli, J. G. Markle, R. Martinez-Barricarte, E. Scott, I. Shah, P. D. Stenson, J. Gleeson, D. N. Cooper, L. Quintana-Murci, S.-Y. Zhang, L. Abel, J.-L. Casanova, The mutation significance cutoff: gene-level thresholds for variant predictions. *Nat. Methods*. **13**, 109–110 (2016).

36. S. L. Masters, M. Gerlic, D. Metcalf, S. Preston, M. Pellegrini, J. A. O'Donnell, K. McArthur, T. M. Baldwin, S. Chevrier, C. J. Nowell, L. H. Cengia, K. J. Henley, J. E. Collinge, D. L. Kastner, L. Feigenbaum, D. J. Hilton, W. S. Alexander, B. T. Kile, B. A. Croker, NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. *Immunity*. **37**, 1009–1023 (2012).
37. N. Kayagaki, I. B. Stowe, B. L. Lee, K. O'Rourke, K. Anderson, S. Warming, T. Cuellar, B. Haley, M. Roose-Girma, Q. T. Phung, P. S. Liu, J. R. Lill, H. Li, J. Wu, S. Kummerfeld, J. Zhang, W. P. Lee, S. J. Snipas, G. S. Salvesen, L. X. Morris, L. Fitzgerald, Y. Zhang, E. M. Bertram, C. C. Goodnow, V. M. Dixit, Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature*. **526**, 666–671 (2015).
38. M. Labow, D. Shuster, M. Zetterstrom, P. Nunes, R. Terry, E. B. Cullinan, T. Bartfai, C. Solorzano, L. L. Moldawer, R. Chizzonite, K. W. McIntyre, Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. *J. Immunol.* **159**, 2452–2461 (1997).
39. S. Mariathasan, K. Newton, D. M. Monack, D. Vucic, D. M. French, W. P. Lee, M. Roose-Girma, S. Erickson, V. M. Dixit, Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. *Nature*. **430**, 213–218 (2004).
40. K. Takeda, H. Tsutsui, T. Yoshimoto, O. Adachi, N. Yoshida, T. Kishimoto, H. Okamura, K. Nakanishi, S. Akira, Defective NK cell activity and Th1 response in IL-18-deficient mice. *Immunity*. **8**, 383–390 (1998).

Acknowledgments: We are grateful to all members of the Masters, Zhong and Reversade laboratories for support. We thank Prof. Anthony Oro (Stanford University) for generous help in fibroblast derivation from family 1. We thank E. Kravets for study coordination and M.W. Allain for data collection (Stanford University). We thank S. Russo for outstanding animal husbandry.

Funding: The Laboratory of Human Genetics of Infectious Diseases is supported by the National Center for Research Resources and the National Center for Advancing Sciences (NCATS) of the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program (UL1TR001866), the French National Research Agency (ANR) under the “Investments for the Future” ANR program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), and the “PNEUMOPID” project (Grant ANR 14-CE15-0009-01), the French Foundation for Medical Research (FRM) (EQU201903007798), the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, Institut National de la Santé et de la Recherche Médicale (INSERM), and the “Université de Paris”. K.L. is supported by a NMRC Open Fund - Young Individual Research Grant (OF-YIRG19MAY-0039). F.L.Z. is an Nanyang Assistant Professor and a recipient of National Research Foundation (NRF, Singapore) fellowship. B.R. is an

investigator of the National Research Foundation (NRF, Singapore) and Branco Weiss Foundation (Switzerland) and an EMBO Young Investigator. This work was funded by a Strategic Positioning Fund for Genetic Orphan Diseases and an inaugural A*STAR Investigatorship from the Agency for Science, Technology and Research in Singapore.

Author contributions: F.L.Z, S.L.M, and B.R designed the study. J.B., D.B., H.K., and N.H. made clinical diagnoses and collected clinical data and samples. C.H, P.L, S.D, C-H.Y and S.L.M performed and supervised the mouse experiments. K.R. and K.L. performed biochemical and cell-based experiments and analyzed the data. C.H, K.R, K. L, F.L.Z, S.L.M and B.R wrote the manuscript with input from all authors.

Competing interests: S.L.M. is a Scientific Advisor for IFM Therapeutics.

Data and materials availability: All data is available in the main text or the supplementary materials.

Supplementary Materials:

Materials and Methods

Figures S1-S4




Fig. 1: Two families segregating recessive *DPP9* germline mutations

(A) Pedigrees of two families harbouring *DPP9* mutations. Proband from Family 1 (II.1) is compound heterozygous, with paternal p.G167S and maternal p.S214* germline mutations. Proband from Family 2 (II.3) carries a homozygous recessive p.Q851* mutation.

(B) Exon-intron genomic organization of *DPP9* with positions of identified germline mutations.

(C) Phylogenetic conservation of the Gly167 residue, which is mutated in Family 1, across vertebrate species.

(D) Protein structure of a *DPP9* homodimer (PDB ID: 6EOR) depicting location of p.G167 on the periphery of the substrate binding site and p.S759 in the catalytic domain.

(E) **Redacted** photographs of proband from Family 2 (II.3) depicting recurrent HSV facial lesions, milia, and skin pigmentation anomalies on his arms.




Fig. 2: Patients' cells lack DPP9 or produce a strong enzymatic hypomorph

(A) Western blot analysis shows reduction of DPP9 protein expression in human dermal fibroblasts isolated from family 1 and family 2 probands. Western blot analysis of DPP9 in primary dermal fibroblasts of an unrelated control (WT/WT) (lane 1), affected individual from family 1 (proband (II:1) S214*/G167S) (lane 2), two unaffected individuals from family 2 ((I:2) and (I:1) Q851*/WT) (lane 3 and 4 respectively) and affected individual from family 2 (proband (II:2) Q851*/Q851*) (lane 5).

(B) DPP8/9 enzyme assay shows a reduction in DPP8/9-derived enzymatic activity in DPP9 S759A and G167S mutants. 293T cells were transfected with either vector, wild-type DPP9, DPP9 S759A or DPP9 G167S and lysed in PBS 1% Tween 20, 48 h after transfection. 0.3 μ g of total lysate was then incubated with Gly-Pro-AMC fluorescence substrate. AMC fluorescence was measured for 20 mins at 25 °C in a 50 μ l reaction every minute on a spectrometer. One-way ANOVA. ****P<0.001 calculated by comparing the vector control to wild-type DPP9, DPP9^{S759A} or DPP9^{G167S}.

(C) DPP9 S759A and G167S mutants have decreased ability to repress NLRP1 inflammasome. 293T-ASC-GFP DPP8/9 DKO cells were transfected with a vector control or WT NLRP1 together with wild-type DPP9, DPP9 S759A, or DPP9 G167S. The percentage of cells with ASC-GFP specks were counted in three different fields after fixation. **P<0.01, ***P<0.001 (one-way ANOVA). n=3 transfections. More than 100 cells were scored per condition.

(D) Family 2 proband primary human keratinocytes experience constitutive inflammasome activation. IL1 β and IL18 ELISA of the culture supernatant from primary keratinocytes from the two unaffected individuals from family 2 ((I:2) and (I:1) (Q851*/WT) and affected individual from family 2 (proband (II:2) Q851*/Q851*). ****P<0.001, ***P<0.01 (one-way ANOVA).

(E) Family 2 proband primary human keratinocytes experience constitutive inflammasome activation. Western blot analysis of inflammasome components in primary keratinocytes of two unaffected individuals from family 2 ((I:2) and (I:1) (Q851*/WT) and an affected individual from family 2 (proband (II:2) Q851*/Q851*). Additionally an unrelated control (+/+), treated with or without the potent DPP8/9 inhibitor Talabostat (2 μ M) was included as a positive control for NLRP1 inflammasome activation.




Figure 3.

Fig. 3: Deficiency of NLRP1 and downstream signaling molecules rescues neonatal lethality of *Dpp9^{S729A/S729A}* mice

a) A viable, 6-month-old male *Dpp9^{S729A/S729A} Nlrp1^{-/-}* mouse is runted compared to a *Dpp9^{S729A/+} Nlrp1^{-/-}* littermate.

- b) *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} mice exhibit stunted weight gain compared to *Dpp9*^{S729A/+} *Nlrp1*^{-/-} controls. Male *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} and *Dpp9*^{S729A/+} *Nlrp1*^{-/-} mice were weighed weekly for 8 weeks post weaning (n=4-5 per genotype).
- c) Decreased stature is associated with decreased hip length but relatively conserved limb measurements, example images of skeletal measurements and d) quantification of 6-month-old *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} and *Dpp9*^{S729A/+} *Nlrp1*^{-/-} mice imaged via MicroCT scanning.
- e) Newborn *Dpp9*^{S729A/S729A} appear visually normal. Images of 3-6 hour-old pups, black arrows indicate presence of milk spots.
- f) FACs analysis of immune cells of the bone marrow and g) blood collected from 3-6 hour-old pups reveals selective monocyte and dendritic cell deficiency from the blood of *Dpp9*^{S729A/S729A} mice.
- h) Post-weaning, the viable *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} mice show no difference in survival compared to *Dpp9*^{S729A/+} *Nlrp1*^{-/-} mice in a Kaplan Meier survival curve, until around 500 days of age (n=8-13 per genotype).
- i) *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} display immune cell infiltrate in lungs. Representative section of lung tissue from 6-month-old *Dpp9*^{S729A/S729A} *Nlrp1*^{-/-} and *Dpp9*^{S729A/+} *Nlrp1*^{-/-} mice stained with Hematoxylin and eosin or immunohistochemistry of F4/80, B220 or CD3 antibodies. (n=3 per genotype).
- j) Genetic analysis of offspring at weaning age was performed from *Dpp9*^{S729A/S729A} crossed to *Nlrp1*^{-/-}, *Gsdmd*^{-/-}, *Ilr-1*^{-/-} *Asc*^{-/-} showing rescue, cross to *Il-18*^{-/-} mice did not confer rescue. Error bars represent mean ±SEM.
- Statistical significance for weight data was determined by a paired t-test. Statistical test for the survival curve was determined by a Mantel-Cox test.

Table 1. Syndrome caused by biallelic Loss-of-Function *DPP9* mutations

<i>Gene</i>	HPO Terms	<i>DPP9</i> (MIM608258)		
Clinical synopsis and genetics				Present in both probands
		Family 1	Family 2	
Propositus number (refer to pedigrees)		II:1	II:3	
Gender		Male	Male	
IUGR, (birth weight in kg)	HP:0001511	+ (2.3)	- (3.6)	
Autosomal recessive inheritance	HP:0000007	compound heterozygous	homozygous	✓
cDNA change (MutationTaster prediction)		maternal: c.641C>G paternal: c.499G>A	c.2551C>T	
Expected protein change (Q86TI2-2)		maternal: p.S214* paternal: p.G167S	p.Q851*	
Observed protein change (Q86TI2-2)		maternal: p.0 paternal: p.G167S	p.0	✓ Loss-of-function mutations
Craniofacial dysmorphisms				
Downslanted palpebral fissures	HP:0000494	+	+	✓
Broad forehead	HP:00002373	+	-	
Bone / skeletal abnormalities				
Proportionate short stature	HP:0003508	+	+	✓
Immune defects				
Infantile eczema	HP:0000964	+ (after BM transplantation)	+	✓
Recurrent fevers	HP:0032323	-	<i>bimonthly</i>	
Asthma	HP:0002099	-	+	
Repeated infections	HP:0002719	+	+	✓
Herpes infections	HP:0005353	-	+ (facial)	
Bronchitis	HP:0012387	+	+	✓
Prone to acute otitis media	HP:0000403	+	+	✓
Pancytopenia	HP:0001876	+	+	✓
Anemia	HP:0001903	+	+	✓
Selective immunodeficiency	HP:0002721	+	+	✓
Severe allergies	HP:0012393	+ (sesame)	+	✓
Behavioural/Neurological traits				
Learning Disability	HP:0001328	+	+	✓
Speech delay	HP:0000750	+	+	✓
Slurred speech	HP:0001350	+	+	✓
Autism spectrum disorder	HP:0000729	+	-	
Skin findings and its appendages				
Thick skin	HP:0001072	+	-	
Anhidrosis	HP:0000970	-	+	
Dry skin	HP:0000958	-	+	✓
Atopic dermatitis	HP:0001047	+	+	✓
Petechiae	HP:0000967	+	+	✓
Fair hair	HP:0002286	+	+	✓
Premature hair graying	HP:0002216	-	+	
Hypo- and hyper-pigmented macules	HP:0007441	+	+	✓
Delayed wound healing	HP:0001058	-	+	
Other clinical manifestations				
Failure to thrive	HP:0001508	+	+	✓
Febrile seizures	HP:0002373	+	-	
Cryptorchidism / hypospadias	HP:0000028	+	-	
Inguinal hernia	HP:0000776	+	-	
Poor feeding	HP:0011968	+	+	✓

n.d., not determined; +, affirmative; -, negative; BM, bone marrow